Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CC-11050

Phase 2Small molecule

CC-11050 is one of 53 small molecule programs targeting Erythema. It is currently in Phase 2.

2

Indications

4

Total Trials

0

Active Trials

52

Competitors

Pipeline

Status by Indication[3][1]

Indication

ErythemaActive, not recruiting

Cutaneous Lupus ErythematosusActive, not recruiting

ErythemaPhase 2

Active, not recruiting

Cutaneous Lupus ErythematosusPhase 2

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Erythema

#DrugCompanyPhaseTrials

Lamprene

Trexall

Alnylam Pharmaceuticals

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Amoxil

GGlobal Antibiotics Research and Development Partnership

Accutane

CConrado Roberto Hoffmann Filho

Botulinum Toxin a

Trimethoprim-Sulfamethoxazole

Alphagan

Ceftin

GGlaxo Dba Glaxosmithkline

Rhofade

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cutaneous Lupus Erythematosus1 trial

To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

Completed· Amgen logo

Amgen·Phase 2·NCT01300208·48 enrolled

Erythema1 trial

CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum

Unknown status·TThe Leprosy Mission Nepal·Phase 2·NCT03807362·50 enrolled

TED1 trial

TB Host Directed Therapy

Unknown status·TThe Aurum Institute NPC·Phase 2·NCT02968927·200 enrolled

Single Dose1 trial

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

Completed· Amgen logo

Amgen·Phase 1·NCT04139226·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CC-11050. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CC-11050 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CC-11050. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Amgen

Related News